...
search icon
dawn-img

Day One Biopharmaceuticals Inc, Common Stock

DAWN

NSQ

$7.74

-$0.16

(-2.03%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$693.26M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
729.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-1.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.41 L
$18.07 H
$7.74

About Day One Biopharmaceuticals Inc, Common Stock

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameDAWNSectorS&P500
1-Week Return8.4%3.64%6.36%
1-Month Return-6.52%-5.42%-5.32%
3-Month Return-39.39%-6.89%-8.86%
6-Month Return-46.99%-7.54%-5.61%
1-Year Return-41.41%-1.81%8.61%
3-Year Return-26.84%2.1%27.58%
5-Year Return-70.1%35.25%90.38%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue----131.16M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue155.00K199.00K531.00K383.00K5.28M[{"date":"2020-12-31","value":2.94,"profit":true},{"date":"2021-12-31","value":3.77,"profit":true},{"date":"2022-12-31","value":10.06,"profit":true},{"date":"2023-12-31","value":7.26,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(155.00K)(199.00K)(531.00K)(383.00K)125.88M[{"date":"2020-12-31","value":-0.12,"profit":false},{"date":"2021-12-31","value":-0.16,"profit":false},{"date":"2022-12-31","value":-0.42,"profit":false},{"date":"2023-12-31","value":-0.3,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin----95.98%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses13.78M72.74M146.91M206.06M343.15M[{"date":"2020-12-31","value":4.02,"profit":true},{"date":"2021-12-31","value":21.2,"profit":true},{"date":"2022-12-31","value":42.81,"profit":true},{"date":"2023-12-31","value":60.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(13.78M)(72.74M)(146.91M)(206.06M)(217.27M)[{"date":"2020-12-31","value":-1378200000,"profit":false},{"date":"2021-12-31","value":-7274300000,"profit":false},{"date":"2022-12-31","value":-14690900000,"profit":false},{"date":"2023-12-31","value":-20606400000,"profit":false},{"date":"2024-12-31","value":-21727000000,"profit":false}]
Total Non-Operating Income/Expense(30.09M)(7.00K)9.47M--[{"date":"2020-12-31","value":-317.62,"profit":false},{"date":"2021-12-31","value":-0.07,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(43.84M)(72.75M)(142.18M)(188.92M)(88.35M)[{"date":"2020-12-31","value":-4384300000,"profit":false},{"date":"2021-12-31","value":-7275400000,"profit":false},{"date":"2022-12-31","value":-14218100000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false},{"date":"2024-12-31","value":-8835200000,"profit":false}]
Income Taxes(3.34M)(2.31M)(10.01M)-(7.14M)[{"date":"2020-12-31","value":-333700000,"profit":false},{"date":"2021-12-31","value":-231200000,"profit":false},{"date":"2022-12-31","value":-1000500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-714400000,"profit":false}]
Income After Taxes(40.51M)(70.44M)(132.18M)--[{"date":"2020-12-31","value":-4050600000,"profit":false},{"date":"2021-12-31","value":-7044200000,"profit":false},{"date":"2022-12-31","value":-13217600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(43.84M)(72.75M)(142.18M)(188.92M)(95.50M)[{"date":"2020-12-31","value":-4384300000,"profit":false},{"date":"2021-12-31","value":-7275400000,"profit":false},{"date":"2022-12-31","value":-14218100000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false},{"date":"2024-12-31","value":-9549600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(40.51M)(70.44M)(132.18M)(188.92M)(95.50M)[{"date":"2020-12-31","value":-4050600000,"profit":false},{"date":"2021-12-31","value":-7044200000,"profit":false},{"date":"2022-12-31","value":-13217600000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false},{"date":"2024-12-31","value":-9549600000,"profit":false}]
EPS (Diluted)(5.99)(6.40)(2.17)(2.38)(1.02)[{"date":"2020-12-31","value":-599.07,"profit":false},{"date":"2021-12-31","value":-640,"profit":false},{"date":"2022-12-31","value":-217,"profit":false},{"date":"2023-12-31","value":-238,"profit":false},{"date":"2024-12-31","value":-102,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

DAWN
Cash Ratio 7.24
Current Ratio 7.66
Quick Ratio 7.61

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DAWN
ROA (LTM) -27.67%
ROE (LTM) -22.49%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DAWN
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DAWN
Trailing PE NM
Forward PE NM
P/S (TTM) 6.10
P/B 1.59
Price/FCF NM
EV/R 2.07
EV/Ebitda NM

FAQs

What is Day One Biopharmaceuticals Inc share price today?

Day One Biopharmaceuticals Inc (DAWN) share price today is $7.74

Can Indians buy Day One Biopharmaceuticals Inc shares?

Yes, Indians can buy shares of Day One Biopharmaceuticals Inc (DAWN) on Vested. To buy Day One Biopharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DAWN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Day One Biopharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Day One Biopharmaceuticals Inc (DAWN) via the Vested app. You can start investing in Day One Biopharmaceuticals Inc (DAWN) with a minimum investment of $1.

How to invest in Day One Biopharmaceuticals Inc shares from India?

You can invest in shares of Day One Biopharmaceuticals Inc (DAWN) via Vested in three simple steps:

  • Click on Sign Up or Invest in DAWN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Day One Biopharmaceuticals Inc shares
What is Day One Biopharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Day One Biopharmaceuticals Inc (DAWN) is $18.07. The 52-week low price of Day One Biopharmaceuticals Inc (DAWN) is $6.41.

What is Day One Biopharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Day One Biopharmaceuticals Inc (DAWN) is 1.59

What is the Market Cap of Day One Biopharmaceuticals Inc?

The market capitalization of Day One Biopharmaceuticals Inc (DAWN) is $693.26M

What is Day One Biopharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Day One Biopharmaceuticals Inc is DAWN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top